Study S001673

Comparative Effectiveness of Semaglutide and Dulaglutide in Patients at Low, Moderate, and High Cardiovascular Risk With Type 2 Diabetes and Overweight

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)

Registration

Registration: NCT07619495
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 120000
Start: 2026-01-20
Primary completion: 2026-06-01
Lead sponsor: Brigham and Women's Hospital
Conditions: Type 2 Diabetes Mellitus; Obesity; Overweight
Interventions: DRUG:Semaglutide; DRUG:Dulaglutide
Results posted: FALSE

Registered primary outcomes

Composite of all-cause mortality, myocardial infarction, or stroke. [1 day after cohort entry until outcome, disenrollment, end of study period, death, 365 days after cohort entry, discontinuation (45 days grace and risk window), switch between study arms, nursing home admission, or start of any other GLP-1-RA]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.